InsiderTrades

Form 4 for AKTX Akari Therapeutics Plc

Accepted 2025-03-10 00:00:00 ET · period of report 2025-03-06 · accession 0000950170-25-036488 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
D 2025-03-10 2025-03-06 AKTX Huh Hoyoung Dir, 10% A - Grant $1.12 +892.9K 4.70M +23% +$1000.0K
DM 2025-03-10 2025-03-06 AKTX Huh Hoyoung Dir, 10% A - Grant $1.12 +1.79M 892.9K New +$2.00M

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common American Depositary Shares representing Ordinary Shares 2025-03-06 A A 892,857 $1.12 4,695,854 D — — (F1) Each American Depositary Share ("ADS") represents 2,000 Ordinary Shares with a par value of $0.0001 per Ordinary Share of the Issuer. (F2) On March 6, 2025, the Reporting Person acquired 892,857 ADS and accompanying Series A and Series B warrants to purchase up to 1,785,714 ADS in a private placement by the Issuer pursuant to the terms of a Securities Purchase Agreement dated as of February 27, 2025. The combined purchase price was $1.12 per ADS and accompanying Series A and Series B warrant.
2 Derivative Series B Warrants (Right to Buy) 2025-03-06 A A 892,857 $1.12 892,857 D $0.87 · 2025-03-06 to 2030-03-06 892,857 American Depositary Shares representing Ordinary Shares (F2) On March 6, 2025, the Reporting Person acquired 892,857 ADS and accompanying Series A and Series B warrants to purchase up to 1,785,714 ADS in a private placement by the Issuer pursuant to the terms of a Securities Purchase Agreement dated as of February 27, 2025. The combined purchase price was $1.12 per ADS and accompanying Series A and Series B warrant.
3 Derivative Series A Warrants (Right to Buy) 2025-03-06 A A 892,857 $1.12 892,857 D $0.87 · 2025-03-06 to 2026-03-06 892,857 American Depositary Shares representing Ordinary Shares (F2) On March 6, 2025, the Reporting Person acquired 892,857 ADS and accompanying Series A and Series B warrants to purchase up to 1,785,714 ADS in a private placement by the Issuer pursuant to the terms of a Securities Purchase Agreement dated as of February 27, 2025. The combined purchase price was $1.12 per ADS and accompanying Series A and Series B warrant.